参考文献/References:
[1]. 《中国心血管健康与疾病报告2021》概述[J].中国心血管病研究,2022,20(07):577-596.
[2]. Waters DD. What the statin trials have taught us[J]. Am J Cardiol,2006,98(1):129-134.
[3]. Gitt AK,Lautsch D,Ferrieres J,et al. Low-density lipoprotein cholesterol in a global cohort 57,885 statin-treated patients[J]. Atherosclerosis,2016,255:200-209.
[4]. Dyrbu? K,Osadnik T,Desperak P,et al. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry[J]. Pharmacol Res,2018,132:204-210.
[5]. Bergeron N,Phan BA,Ding Y,et al. Proprotein convertase subtilisin/kexin type 9 inhibition:a new therapeutic mechanism for reducing cardiovascular disease risk[J]. Circulation,2015,132(17):1648-1666.
[6]. Dragan S,Serban MC,Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors:an emerging lipid-lowering therapy?[J]. J Cardiovasc Pharmacol Ther ,2015,20(2):157-168.
[7]. Seidah NG,Benjannet S,Wickham L,et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):liver regeneration and neuronal differentiation[J]. Proc Natl Acad Sci U S A,2003,100(3):928-933.
[8]. Barale C,Melchionda E,Morotti A,et al. PCSK9 biology and its role in atherothrombosis[J]. Int J Mol Sci,2021,22(11):5880.
[9]. Kosmas CE,Mu?oz Estrella A,Sourlas A,et al. Inclisiran:a new promising agent in the management of hypercholesterolemia[J]. Diseases,2018,6(3):63.
[10]. Kosmas CE,Mu?oz Estrella A,Skavdis A,et al. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential [J]. Ther Clin Risk Manag,2020,16:1031-1037.
[11]. Malo J, Parajuli A, Walker SW. PCSK9:from molecular biology to clinical applications[J]. Ann Clin Biochem,2020,57(1):7-25.
[12]. Kuzmich N,Andresyuk E,Porozov Y,et al. PCSK9 as a target for development of a new generation of hypolipidemic drugs[J]. Molecules,2022,27(2):434.
[13]. Fitzgerald K,Frank-Kamenetsky M,Shulga-Morskaya S,et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers:a randomised,single-blind,placebo-controlled,phase 1 trial. Lancet,2014,383(9911):60-68.
[14]. Fitzgerald K,White S,Borodovsky A,et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med,2017,376(1):41-51.
[15]. Lagace TA,Curtis DE,Garuti R,et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11):2995-3005.
[16]. Kosmas CE,DeJesus E,Morcelo R,et al. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9):an emerging chapter in lipid-lowering therapy[J]. Drugs Context,2017,6:212511.
[17]. Ray KK,Stoekenbroek RM,Kallend D,et al. Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins:prespecified secondary end points in ORION 1[J]. Circulation,2018,138(13):1304-1316.
[18]. Ray KK,Landmesser U,Leiter LA,et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med,2017,376(15):1430-1440.
[19]. Henney NC,Banach M,Penson PE. RNA silencing in?themanagement ofdyslipidemias[J]. Curr Atheroscler Rep,2021,23(11):69.
[20]. Hovingh GK,Lepor NE,Kallend D,et al. Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia:the ORION-2 pilot study[J]. Circulation,2020,141(22):1829-1831.
[21]. Kosmas CE,Mu?oz Estrella A,Sourlas A,et al. Inclisiran in dyslipidemia[J]. Drugs Today (Barc), 2021,57(5):311-319.
[22]. Kallend D,Stoekenbroek R,He Y,et al. Pharmacokinetics and pharmacodynamics of inclisiran,a small interfering RNA therapy,in patients with hepatic impairment[J]. J Clin Lipidol,2022,16(2):208-219.
[23]. Kallend D,Mason J,Smith PF,et al. An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers:A phase I,randomized study[J]. Clin Transl Sci,2022,15(11):2663-2672.
[24]. Toth PP,Bray S,Villa G,et al. Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol[J]. J Am Heart Assoc,2022,11(18):e025551.
[25]. Hardy J,Niman S,Pereira E,et al. A critical review of the efficacy and safety of inclisiran. Am J Cardiovasc Drugs,2021,21(6):629-642.
[26]. Landmesser U,Haghikia A,Leiter LA,et al. Effect of inclisiran,the small-interfering RNA against proprotein convertase subtilisin/kexin type 9,on platelets,immune cells,and immunological biomarkers:a pre-specified analysis from ORION-1[J]. Cardiovasc Res,2021,117(1):284-291.
[27]. Galactionova K,Salari P,Mattli R,et al. Cost-effectiveness,burden of disease and budget impact of inclisiran:dynamic cohort modelling of a real-world population with cardiovascular disease[J]. Pharmacoeconomics,2022,40(8):791-806.
[28]. Desai NR,Campbell C,Electricwala B,et al. Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated lowdensity lipoprotein cholesterol despite statin use:a threshold analysis[J]. Am J Cardiovasc Drugs,2022,22(5):545-556.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(7):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(7):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(7):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(7):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(7):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]